Mandate

Vinge has advised SmartCella Holding AB in connection with fund raising

July 08, 2024 M&A

Vinge has advised SmartCella Holding AB in connection with its fund raising of EUR 50 million. The capital was invested by, among others, AstraZeneca, the Fourth Swedish National Pension Fund, AMF Pension, SEB-Stiftelsen, Handelsbanken Fonder and RoosGruppen AB. SmartCella is a world-leading biotechnology company pioneering the future of targeted therapies by combining first-in-class delivery platforms with cutting-edge cell and gene therapies.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025